Summary & Overview
Coronary Bypass with PTCA with MCC: Inpatient Reimbursement Overview
DRG 231 describes coronary artery bypass grafting combined with percutaneous transluminal coronary angioplasty when a Major Complication or Comorbidity is present, encompassing high-complexity cardiac revascularization. Proper assignment influences inpatient reimbursement because the additional complication or comorbidity increases expected resource use and payment under Medicare.
DRG 231 Overview
DRG 231 covers inpatient hospitalizations for coronary artery bypass grafting combined with percutaneous transluminal coronary angioplasty when a Major Complication or Comorbidity is present. This Diagnosis-Related Group applies to complex revascularization cases where both surgical and percutaneous procedures are performed and significant additional diagnoses increase resource use. It matters for Medicare inpatient payment because the presence of a Major Complication or Comorbidity raises the relative weight and reimbursement, reflecting higher expected costs of care. Accurate clinical coding and documentation determine assignment to this Diagnosis-Related Group and therefore materially affect hospital payment.
Clinical Trials
- Acute procedural optimization trials: randomized or pragmatic studies comparing different intraoperative strategies during combined coronary artery bypass grafting (CABG) plus percutaneous transluminal coronary angioplasty (PTCA) procedures, such as timing of grafting versus stenting, use of on-pump versus off-pump techniques, or adjunctive hemodynamic support. These trials enroll high-risk inpatients undergoing concurrent bypass and catheter-based revascularization, focusing on perioperative myocardial infarction, bleeding, need for repeat revascularization, and short-term mortality. Results are directly relevant to surgeons, interventionalists, and hospital administrators because they can influence operative protocols, resource utilization in the OR/cath lab, and immediate complication rates that drive DRG costs and length of stay.
- Comparative effectiveness and care-pathway studies in the early postoperative period: observational cohort studies or pragmatic randomized trials comparing enhanced recovery pathways, antithrombotic regimens, or intensity of monitoring (eg, ICU versus step-down) for patients after combined CABG+PTCA, stratified by comorbidity burden and presence of major complications (MCCs). These studies target the subpopulation represented by DRG 231 — medically complex patients with multiple comorbidities or procedural complications — to determine which postoperative strategies reduce readmissions, major adverse cardiac events, and transfusion/ventilation days. Payers and hospitals find this research valuable because it identifies care models that can shorten length of stay, lower complication-related costs, and improve discharge disposition for a high-cost DRG.
- Longitudinal outcomes and health-services research on post-discharge morbidity and resource use: cohort or registry-based studies following patients after hospital discharge to assess medium- and long-term outcomes such as graft/patency failure, recurrent ischemia requiring reintervention, functional status, quality of life, and total downstream healthcare utilization. These studies often examine risk factors present during the index hospitalization (eg, intraoperative events, transfusions, renal injury) that predict readmission or major adverse cardiac and cerebrovascular events in this high-risk group. The findings inform risk-adjustment models, bundled-payment planning, and targeted transitional-care interventions that payers and providers use to manage long-term costs and improve value for patients categorized under this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.